Literature DB >> 32731101

A meta-analysis of clinical predictors for renal recovery and overall mortality in acute kidney injury requiring continuous renal replacement therapy.

Panupong Hansrivijit1, Keerthi Yarlagadda2, Max M Puthenpura3, Nasrollah Ghahramani4, Charat Thongprayoon5, Pradeep Vaitla6, Wisit Cheungpasitporn7.   

Abstract

PURPOSE: To determine clinical predictors for continuous renal replacement therapy (CRRT) discontinuation in patients with acute kidney injury (AKI).
MATERIALS AND METHODS: Ovid MEDLINE, EMBASE, and Cochrane Library were searched. The protocol is registered on researchregistry.com (reviewregistry909). Our criteria included non-end-stage kidney disease adults who required CRRT for AKI. Renal recovery was defined by CRRT discontinuation. Risk of bias was assessed using ROBINS-I tool.
RESULTS: We classified our analyses into renal recovery cohort and overall mortality cohort. All studies were observational. For renal recovery cohort, increasing urine output at time of CRRT discontinuation, elevated initial SOFA score and serum creatinine at CRRT initiation were predictive of renal recovery with OR 1.021 (95%CI = 1.011-1.031), 0.869 (95%CI = 0.811-0.932) and 0.995 (95%CI = 0.996-0.999), respectively. For overall mortality cohort, age and presence of sepsis were significantly associated with overall mortality with OR of 1.028 (95%CI = 1.008-1.048) and 2.160 (95%CI = 0.973-1.932), respectively.
CONCLUSIONS: Urine output at CRRT discontinuation, lower initial SOFA score, and lower serum creatinine levels at CRRT initiation were associated with higher likelihood of renal recovery. Increasing age and the presence of sepsis were associated with increased overall mortality from AKI on CRRT. However, there were limited data on co-morbidities which might preclude their inclusion in our analysis.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKI; Acute kidney injury; CRRT; Continuous renal replacement therapy; Renal recovery

Mesh:

Substances:

Year:  2020        PMID: 32731101     DOI: 10.1016/j.jcrc.2020.07.012

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  6 in total

1.  Echocardiographic parameters and hemodynamic instability at the initiation of continuous kidney replacement therapy.

Authors:  Panagiotis Kompotiatis; Khaled Shawwa; Jacob C Jentzer; Brandon M Wiley; Kianoush B Kashani
Journal:  J Nephrol       Date:  2022-07-18       Impact factor: 4.393

Review 2.  Factors Associated with In-Hospital Mortality after Continuous Renal Replacement Therapy for Critically Ill Patients: A Systematic Review and Meta-Analysis.

Authors:  Hyeon-Ju Lee; Youn-Jung Son
Journal:  Int J Environ Res Public Health       Date:  2020-11-26       Impact factor: 3.390

Review 3.  Continuous renal replacement therapy and the COVID pandemic.

Authors:  Jacob S Stevens; Juan Carlos Q Velez; Sumit Mohan
Journal:  Semin Dial       Date:  2021-03-11       Impact factor: 2.886

4.  A methodologic survey on use of the GRADE approach in evidence syntheses published in high-impact factor urology and nephrology journals.

Authors:  Shuang Zhang; Qi-Jun Wu; Shu-Xin Liu
Journal:  BMC Med Res Methodol       Date:  2022-08-10       Impact factor: 4.612

5.  Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19.

Authors:  Gaetano Alfano; Annachiara Ferrari; Francesco Fontana; Giacomo Mori; Riccardo Magistroni; Marianna Meschiari; Erica Franceschini; Marianna Menozzi; Gianluca Cuomo; Gabriella Orlando; Antonella Santoro; Margherita Digaetano; Cinzia Puzzolante; Federica Carli; Andrea Bedini; Jovana Milic; Irene Coloretti; Paolo Raggi; Cristina Mussini; Massimo Girardis; Gianni Cappelli; Giovanni Guaraldi
Journal:  Clin Exp Nephrol       Date:  2021-07-01       Impact factor: 2.801

6.  Prediction and Clinically Important Factors of Acute Kidney Injury Non-recovery.

Authors:  Chien-Liang Liu; You-Lin Tain; Yun-Chun Lin; Chien-Ning Hsu
Journal:  Front Med (Lausanne)       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.